OASIS PHARMACEUTICALS, LLC
- LEXINGTON, MA 02420-1226
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
OASIS PHARMACEUTICALS, LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About OASIS PHARMACEUTICALS, LLC
- Headquarters
- LEXINGTON, MA 02420-1226
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIF2ZWBFV5NZ86
- CAGE6G7D5
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 12 awards
- Total awarded
- $12,292,756
- By phase
- STTR Phase I: 7
- STTR Phase II: 4
- SBIR Phase II: 1
- By agency
- Department of Health and Human Services: 12
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2023: 1
- 2022: 1
- 2021: 1
- 2019: 1
- 2018: 1
- 2017: 2
- 2016: 1
- 2015: 1
- 2014: 1
- 2013: 1
Awards (most recent first)
Development of PAR2 Pepducins for the Treatment of COPD
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $468,369
Sep 15, 2025 – Feb 28, 2026
Solicitation PA24-247 (2024) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,049,598
Feb 1, 2023 – Jan 31, 2025
Solicitation PA20-272 (2020) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
Development of liver homing PAR2 pepducins for the treatment of HepatocellularCarcinoma
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $392,485
Sep 1, 2022 – Aug 31, 2023
Solicitation PA21-262 (2021) · Topic NCI · Research partner: TUFTS MEDICAL CENTER
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $361,774
Sep 1, 2021 – Feb 28, 2022
Solicitation PA20-265 (2020) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,491,074
Apr 1, 2019 – Mar 31, 2021
Solicitation PA17-303 (2017) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,769
May 15, 2018 – Oct 31, 2020
Solicitation PA17-303 (2017) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
Development of PAR2 Pepducins as a Novel NASH Treatment
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $3,165,348
Sep 20, 2017 – Aug 31, 2020
Solicitation PA16-302 (2016) · Topic 300
Development of PAR Pepducins as a Novel Antithrombotic Treatment
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $366,484
May 1, 2017 – Apr 30, 2018
Solicitation PA15-270 (2015) · Topic NHLBI · Research partner: TUFTS MEDICAL CENTER
Development of PAR Pepducins for the Treatment of Atopic Dermatitis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,500,000
Sep 1, 2016 – Aug 31, 2019
Solicitation PA14-072 (2014) · Topic NIAMS · Research partner: TUFTS MEDICAL CENTER
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $225,000
Sep 1, 2015 – May 31, 2016
Solicitation PA14-072 (2015) · Topic NIAMS · Research partner: TUFTS MEDICAL CENTER
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,742,618
May 20, 2014 – Feb 28, 2017
Solicitation PA13-089 (2014) · Topic NIDDK · Research partner: TUFTS MEDICAL CENTER
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $304,237
Solicitation PA13-089 (2013) · Topic NIDDK · Research partner: TUFTS MEDICAL CENTER
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with OASIS PHARMACEUTICALS, LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.